Syndax Pharmaceuticals (SNDX) Income from Continuing Operations: 2015-2024
Historic Income from Continuing Operations for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Dec 2024 value amounting to -$318.5 million.
- Syndax Pharmaceuticals' Income from Continuing Operations fell 39.81% to -$19.9 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$71.4 million, marking a year-over-year decrease of 24.13%. This contributed to the annual value of -$318.5 million for FY2024, which is 52.40% down from last year.
- According to the latest figures from FY2024, Syndax Pharmaceuticals' Income from Continuing Operations is -$318.5 million, which was down 52.40% from -$209.0 million recorded in FY2023.
- Over the past 5 years, Syndax Pharmaceuticals' Income from Continuing Operations peaked at $24.7 million during FY2021, and registered a low of -$318.5 million during FY2024.
- Moreover, its 3-year median value for Income from Continuing Operations was -$209.0 million (2023), whereas its average is -$225.5 million.
- In the last 5 years, Syndax Pharmaceuticals' Income from Continuing Operations surged by 133.90% in 2021 and then tumbled by 702.74% in 2022.
- Yearly analysis of 5 years shows Syndax Pharmaceuticals' Income from Continuing Operations stood at -$72.9 million in 2020, then spiked by 133.90% to $24.7 million in 2021, then plummeted by 702.74% to -$149.0 million in 2022, then plummeted by 40.25% to -$209.0 million in 2023, then plummeted by 52.40% to -$318.5 million in 2024.